The Filing Desk

Cerus

CERS · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

CERS · Last close · November 13, 2026
$1.99
Value Cerus yourself

Cerus' revenue rose 16.1% to $234 million in fiscal 2025. Its operating margin was −3.7%, up from −7.1% a year earlier. Free cash flow was $1 million, down 87.0%. The diluted share count rose 3.3%.

CERUS CORP Latest fiscal year ended December 31, 2025 10-K filed March 2, 2026 · 0001193125-26-085678 Updated
Revenue
$234M
16.1%
Operating margin
−3.7%
3.4 pts
Net income
−$16M
 
Free cash flow
$1M
87.0%
Return on equity
−26.0%
12.5 pts
Market cap
$400M
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Cerus does

Cerus develops and sells the INTERCEPT Blood System, a set of products that reduce viruses, bacteria and parasites in donated blood before it is given to patients. It is used with platelets, which help blood clot, and with plasma, the liquid part of blood. It also makes a fibrinogen product used to treat serious bleeding.

The platelet and plasma systems have FDA approval in the United States and the European CE Mark, and are sold in the U.S., parts of Europe, the Middle East, Latin America and other regions. Buyers are blood centers and hospitals. Cerus also earns revenue from U.S. government contracts, including with BARDA and the Department of Defense, which help pay for its development work.

A version for red blood cells is not yet sold anywhere. It is in a late-stage clinical trial, and its European approval application has had to be resubmitted. Cerus relies on Fresenius Kabi and other outside companies to make parts of the system. The company was founded in California in 1991 and now has a Dutch subsidiary.

Its biggest risks, as it describes them

  • The red blood cell system may never win approvals or European certification.
  • Its development funding depends in part on U.S. government agreements that could be cut or ended.
  • It relies on Fresenius Kabi and other third parties to make parts of its system.
  • It expects continued losses and has limited sales and marketing experience in the U.S.
  • Its system may not be compatible with some commercial platelet collection methods.
From Cerus's annual report on Form 10-K, filed March 2, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Cerus lost money in fiscal 2025: a net loss of $16 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments129102668083
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage−9.9x−5.8x−3.6x−1.6x−1.0x
Current ratio2.4x1.4x2.1x2.4x1.7x
Quick ratio2.0x1.2x1.6x1.8x1.2x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Cerus' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Cerus says to expect

  • Full year 2026: product revenueThe Company continues to expect full-year 2026 product revenue to be in the range of $229 million to $231 million, reflecting growth of 11% to 12% from 2025. Included in this range is full-year 2026 IFC revenue guidance of $23 million to $25 million.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 2, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

No officer, director or 10% owner of Cerus reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−26.4%12.0%16.6%
Altman Z''−15.30−14.46−13.54
Accruals ratio2.7%−16.2%−9.7%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailPassPass
Return on assets rosePassPassPass
Cash from operations exceeds net incomeFailPassPass
Debt fell relative to assets———
Current ratio rosePassPassFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassPassPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Cerus side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
CerusFY2516.1%−3.7%0.5%———
OrthopediatricsFY2515.4%−16.6%−6.8%−8.2%—4Compare
STAAR SurgicalFY25−23.7%−38.3%−16.7%———Compare
AxogenFY2520.2%−3.5%−1.3%−4.9%—5Compare
LeMaitre VascularFY2513.5%27.2%29.8%25.5%−2.4x5Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue39517694114160188187201234
Revenue growth14.8%30.7%48.2%23.3%21.8%39.6%18.1%−0.8%7.8%16.1%
Gross profit1729446073—————
Research and development31344360646464685968
Operating income−61−58−55−66−58−49−34−30−14−9
Net income−63−61−58−71−60−54−43−38−21−16
Diluted EPS (US$)−0.62−0.56−0.44−0.51−0.37−0.32−0.24−0.21−0.11−0.08
Diluted shares (millions)102108132140164171176180185191
Cash flow
Cash from operations−54−52−31−66−42−34−26−43115
Capital expenditure1019212534
Free cash flow−54−53−32−74−43−35−28−4891
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation891013182424202323
Balance sheet at fiscal year end
Cash and short-term investments686111886134129102668083
Debt incl. finance leases——————————
Total assets10498164166221238218198201222
Total liabilities465979108118152150144144157
Shareholders' equity583984571048568535664
Margins and ratios
Gross margin43.0%56.1%58.4%64.4%64.0%—————
Operating margin−156.4%−112.1%−72.3%−70.6%−51.1%−30.7%−18.1%−16.1%−7.1%−3.7%
Net margin−160.2%−118.0%−75.7%−76.0%−52.4%−34.1%−22.7%−20.1%−10.4%−6.7%
Free cash flow margin−137.7%−102.5%−42.6%−79.4%−38.0%−21.8%−14.7%−25.6%4.2%0.5%
Rule of 40 (growth + FCF margin)−123.0%−71.8%5.6%−56.1%−16.2%17.8%3.4%−26.4%12.0%16.6%
Return on capital——————————
Return on equity−82.5%−125.3%−93.2%−100.7%−74.4%−57.7%−56.2%−62.4%−38.5%−26.0%
Return on assets−51.8%−60.1%−44.0%−43.3%−30.9%−23.7%−18.8%−18.0%−10.5%−7.4%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Cerus' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Cerus.